BioPharmSignal logoBioPharmSignal

Biotech News

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

IRIDEX (IRIX)IRIDEXFinancing

MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its

Related news

PRQRProQR Therapeutics2026-06-25 10:35 EST

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:06 EST

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

XAIRBeyond Air2026-07-30 11:00 EST

Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

ICCMIceCure Medical2026-06-17 17:14 EST

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

ICCMIceCure Medical2026-08-06 12:05 EST

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

View all latest news

IRIDEX

IRIDEX is a medical device company focused on ophthalmic laser systems and eye-care procedures. Its business is built around retina and glaucoma treatment platforms.

Recent company news

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

IRIXIRIDEX2026-05-19 20:05 EST

Iridex Reports First Quarter 2026 Financial Results

IRIXIRIDEX2026-05-05 20:05 EST

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

Stock data

Close
0.84 USD
Market cap
20.37M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States